Children are beginning to return to school under new social distancing rules and regulations. We have been contacted by concerned parents and school staff about how the COVID-19 epidemic and the restrictions in place because of it, affect the giving

The largest European quantitative study on peanut allergy has highlighted varying levels of effective disease management between countries, as well as the associated feelings of uncertainty, stress and isolation experienced by those with peanut allergy and their caregivers. APPEAL-1 (Allergy to Peanuts

This is a recall for Emerade 500 microgram pens only. This is a different alert to that issued on 04 March 2020 for Emerade 150 microgram auto-injectors and on 07 April 2020 for Emerade 300 microgram auto-injectors. Results from manufacturer

The Anaphylaxis Campaign, a UK charity that supports the growing number of adults and children affected by severe allergies, has today (6 May 2020) announced its new president, former vice-president David Reading OBE. On 2 April, the charity was notified

In the run-up to our annual Anaphylaxis Awareness Week (4 – 10 May), the Anaphylaxis Campaign would like to welcome our new youth ambassador Dan Kelly, founder of the ‘May Contain’ blog (Instagram @_maycontain) and podcast, who will be working with us to support and empower

The Anaphylaxis Campaign recently became aware of news reports in the media stating that major supermarkets had introduced new social distancing rules in store, asking customers not to touch food items unless they intended to buy them, and suggesting that

Mylan’s manufacturing partner Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen®, had previously experienced manufacturing challenges which resulted in interruptions in the supply of EpiPen Jr 0.15mg and EpiPen 0.3mg Adrenaline Auto-Injectors (AAIs). Supply has stabilised further in

The Anaphylaxis Campaign is aware of a number of companies offering intravenous vitamins which they claim can boost nutritional wellbeing. As a charity that supports the allergic community, we have concerns about the potential risks of these treatments should the companies

Our 2019 impact report is now available to view online. Every year we look back at the differences we have made to the allergic community and announce our vision for the future. In 2019 we celebrated our 25th anniversary and